CCAAT-enhancer-binding protein delta (C/EBPd) is a transcription factor mainly known for its role in inflammation and apoptosis/proliferation. Considering that these are key processes in renal fibrosis, we hypothesized that C/EBPd would potentiate renal fibrosis. In line with this hypothesis, C/EBPd has recently been suggested to regulate the fibrotic response during glomerulonephritis. Here we determined the importance of C/EBPd in the development of renal tubulointerstitial fibrosis by subjecting 8-to 12-week-old C/EBPd-deficient mice and age-and sex-matched wild-type controls to the unilateral ureteral obstruction model. Mice were killed at 1, 3, or 7 days post surgery, and renal tissues were obtained for RNA, protein, and immunohistochemical analysis. We show that C/EBPd deficiency resulted in a more profound fibrotic response as evident from enhanced tubular injury, collagen deposition in the interstitial area, and higher expression of transforming growth factor-b. Moreover, we show that the increase in renal fibrosis in C/EBPd-deficient mice does not depend on an altered proliferation/apoptosis balance or on a differential inflammatory response in the obstructed kidney. In conclusion, our study provides direct evidence that C/EBPd is a novel mediator of renal fibrosis. Modulating C/EBPd expression could consequently be a potential antifibrotic strategy in patients with chronic kidney disease.
Tissue fibrosis is, in general, a hallmark of chronically failing organs and is a leading cause of morbidity and mortality. 1 Renal fibrosis is not an exception and is indeed a major risk factor for the progression to end-stage renal disease and consequently a strong predictor for renal disease outcome. 2 Interestingly, in most renal diseases, irrespective of the originating compartment, interstitial fibrosis is the principal common pathway leading to end-stage renal disease (ESRD). 3 Although not completely understood, renal fibrosis is probably initiated by a robust inflammatory response, which occurs upon disruption of normal tubular integrity 4, 5 and the loss of the renal capillary network. 6, 7 Subsequently, the accumulation of interstitial leukocytes and myofibroblasts leads to excessive extracellular matrix (ECM) production eventually leading to tubular atrophy and loss of renal function. [8] [9] [10] The different stages of obstructive nephropathy leading to tubulointerstitial fibrosis are frequently studied using the wellestablished murine unilateral ureteral obstruction (UUO) model. 4 In this particular model, tubulointerstitial disease is associated with progressive tubular cell loss and atrophy caused by an imbalance in proliferation and apoptosis. 9, 11 Moreover, a strong increase in the accumulation of macrophages in the tubulointerstitial compartment is observed. 9, 12 Next to these 'early' events, transforming growth factor (TGF)-b expression is induced, which is highly relevant, as TGF-b is an important mediator of fibrosis by mediating (myo)fibroblast proliferation and accumulation, epithelial to mesenchymal transition, and ECM production. 13, 14 CCAAT-enhancer-binding protein (C/EBP) d is a member of the C/EBP family of transcription factors. 15 Originally identified as a transcription factor that is rapidly upregulated during the acute phase response, shortly after its discovery, C/ EBPd was already implicated in cell proliferation. Nowadays C/EBPd is believed to act as a tumor suppressor because of its ability to decrease expression of cell cycle proteins cyclin D1 and cyclin E, while increasing the expression of p27. [16] [17] [18] Moreover, C/EBPd regulates pro-apoptotic gene expression during mammary gland involution 19, 20 and inhibits the growth of human cell lines from different tumor types in vitro. 16, 21, 22 In line, increased mammary epithelial cell proliferation and ductal hyperplasia is one of the main features observed in C/EBPd-deficient mice. 23 Together, these data suggest that C/EBPd has an important role in the balance between cell proliferation and apoptosis.
Recently, C/EBPd expression in macrophages emerges as a key process in pathophysiology. Indeed, we recently showed that macrophage recruitment during Klebsiella-induced pulmonary infection is markedly reduced in C/EBPd-deficient mice, and the reduced number of macrophages correlated with reduced Klebsiella-induced mortality in C/EBPd-deficient mice. 24 Moreover, C/EBPd modulates the expression of CCL20, interleukin (IL)-23, CXCL1, and TNFAIP6 in macrophages, and these C/EBPd targets subsequently potentiate the pathogenesis of rheumatoid arthritis, 25 whereas macrophage C/EBPd also induces phagocytosis of apoptotic neuronal cells. 26 Finally, a recent paper shows that C/EBPd directly drives LPS-induced tumor necrosis factor-a, IL-6, and macrophage inflammatory protein-2 in pulmonary macrophages, 27 which may be due to C/EBPd-dependent tolllike receptor-4 expression. 28 Interestingly, C/EBPd also modifies renal inflammation, as C/EBPd deficiency protected against Habu snake venom-induced glomerulonephritis. In this particular model, C/EBPddeficient mice showed reduced smooth muscle a-actin (aSMA) expression in the glomeruli and diminished deterioration of renal function as compared with wild-type mice. 29 Whether C/EBPd-dependent aSMA expression is causally linked to Habu-venom-induced renal dysfunction, however, remains to be established.
Overall, C/EBPd might thus be involved in some of the key processes leading to tubulointerstitial fibrosis, and therefore we hypothesized that C/EBPd would aggravate renal fibrosis. We challenged this hypothesis by evaluating renal fibrosis in wild-type and C/EBPd-deficient mice subjected to the unilateral ureter obstruction (UUO) model. Surprisingly, we show that C/EBPd limits UUO-induced renal fibrosis, and this protective effect of C/EBPd seems independent of the proliferation/apoptosis balance or of the infiltration of macrophages.
MATERIALS AND METHODS Mice
Specific pathogen-free 8-to 12-week-old female C57BL/6 mice were purchased from Charles River and C/EBPd-deficient mice (on a C57BL/6 background; generated as described previously 30 ) were bred in the animal facility of the Academic Medical Center with free access to food and water. Mice used for experiments were age and sex matched. The Animal Care and Use Committee of the University of Amsterdam approved all animal experiments.
Experimental Model
Mice were subjected to the well-established model of renal progressive injury (ie, unilateral ureteral obstruction; UUO) as described previously. 31 Before surgery, all mice received analgesia (subcutaneous injection of 50 mg/kg buprenorphine (Temgesic; Shering-Plough)). During surgery, the right ureter was ligated with 6-0 silk surgical suture through a small abdominal incision under 2.0% isoflurane-induced anesthesia. Subsequently, the abdomen was closed. Mice were killed 1, 3, or 7 days after surgery, and kidneys were collected for further analysis. Contralateral non-obstructed kidneys served as control as described before. 31, 32 Histopathological Scoring To score renal injury, formalin-fixed paraffin embedded PAS-D-stained slides were analyzed by a pathologist (S.F.) in a blinded manner with respect to the following parameters: tubular dilatation, epithelial simplification, and interstitial expansion. Lesions were graded on a scale from 0 to 4: 0 ¼ normal; 1 ¼ mild, involvement of less than 25% of the cortex; 2 ¼ moderate, involvement of 25 to 50% of the cortex; 3 ¼ severe, involvement of 50 to 75% of the cortex; 4 ¼ extensive damage involving more than 75% of the cortex. Edema as evident from increased interstitial space was also graded in a blinded manner according to the following: 0 ¼ normal; 1 ¼ mild, 2 ¼ moderate, and 3 ¼ severe amount of edema. The final score of each slide was the average of 10 randomly chosen, non-overlapping fields in the cortex of the obstructed kidney at a Â 400 magnification.
Immunohistochemistry C/EBPd protein expression was determined using a rabbitanti C/EBPd antibody (#2318; Cell Signaling Technologies) as described before. 33 Collagen staining was performed using a rabbit-anti-collagen type I (GTX41286; GeneTex) antibody as described before. 34 Proliferative and apoptotic cells were detected using rabbit anti-Ki67 (#RM-9106; Lab Vision) and anticleaved caspase-3 (#9661S; Cell Signaling Technologies) antibodies essentially as described before. 35 In short, after deparaffinization and endogenous peroxidase inhibition, slides were boiled in citrate buffer (pH6.0) for 10 min, blocked with normal goat serum for 30 min, and incubated overnight with the primary antibody (1:1000 for C/EBPd, 1:500 for Ki67, 1:200 for cleaved caspase-3 and 1:400 for collagen type I) at 4 1C. Subsequently, slides were incubated with Powervision PolyHRP-anti-rabbit IgG (DPVR-55HRP; Immunologic) for 30 min at room temperature and stained using DAB (BS04-999; Immunologic).
Co-localization of tubular segmentation markers with C/EBPd was assessed using rabbit-anti-SGLT2 (proximal tubules) and rabbit-anti-NCC (distal tubules) antibodies. After performing the C/EBPd staining as described above, slides were boiled in citrate buffer (pH6.0) for 10 min and incubated overnight with the primary antibody (1:400 for SGLT2 and 1:800 for NCC) at 4 1C. Subsequently, slides were incubated with Powervision PolyAP-anti-rabbit IgG (DPVR-55AP; Immunologic) for 30 min at room temperature and stained using the Vector Blue Alkaline Phosphatase Substrate Kit (SK-5300; Vector Labs).
Detection of Macrophages
Macrophage staining was carried out using a rat-anti-F4/80 antibody (MCA497GA; AbD Serotec) as described before. 24 In short, slides were deparaffinized and endogenous peroxidase was inhibited by 0.3% H 2 O 2 in methanol for 10 min. Slides were boiled in citrate buffer (pH6.0) for 20 min, blocked with Ultra V block for 10 min, and incubated overnight with the primary antibody (1:500) at 4 1C. Sections were then incubated with a Rabbit (FAB2)-anti-rat IgG (#6130-01; ITK Diagnostics) 1:3000 in 20% Normal Mouse Serum/PBS for 30 min. Subsequently, slides were incubated with Powervision PolyHRP-anti-rabbit IgG (DPVM-55HRP; Immunologic) for 30 min at room temperature and stained using DAB (BS04-999; Immunologic).
Cytokine Detection
Active TGF-b and hepatocyte growth factor (HGF) levels were measured using ELISA (R&D Systems) according to the manufacturer's recommendations.
RNA Isolation and RT-PCR
For gene expression analysis, mRNA was isolated from kidney homogenates using Tripure isolation reagent (#11667165001; Roche Diagnostics) according to the manufacturer's recommendations. All mRNA samples were quantified by spectrophotometry and stored at À 80 1C until further analysis. mRNA was DNAase treated (#M6101; Promega, the Netherlands) after which cDNA was prepared. Gene expression analysis was performed using a Roche lightcycler with SYBR green PCR master mix (#04707516001; Roche) using the QuantiTect mouse c/ebpd primer assay kit (#QT00312809; Qiagen Benelux).
Western Blot
After electrophoresis of the samples on a 12.5% SDS-PAGE gel, proteins were transferred onto Immobilon-P membranes (Millipore). The blots were blocked for 1 h at room temperature in 5% Bovine Serum Albumin (BSA) in TBS þ 0.1% Tween-20 (TBS-T). Rabbit-anti-C/EBPd (#2318; Cell Signaling Technologies) and mouse-anti-b-actin (sc-81178; Santa Cruz Biotechnology) were diluted 1:1000 in TBS-T supplemented with 5% (C/EBPd) or 1% (b-actin) BSA. Membranes were incubated overnight at 4 1C, washed in TBS-T, and incubated with a HRP-linked secondary antibody (1:1000 in TBS-T). After 1 h of incubation at room temperature, blots were washed in TBS-T and imaging was performed using Lumi-Light (12015200001; Roche) and an ImageQuant LAS 4000 biomolecular imager for chemiluminescence (GE Healthcare).
Statistics
Differences between groups were analyzed using a t-test if data in all groups were normally distributed or with a Mann-Whitney U-test when the data were not normally distributed. Analyses were performed using GraphPad Prism version 5.0.
RESULTS

Unilateral Ureteral Obstruction Induces C/EBPd Expression
In order to determine whether C/EBPd might have a role during UUO-induced fibrosis, we first assessed C/EBPd expression during UUO. To this end, C/EBPd mRNA levels in control and obstructed kidneys of wild-type mice were analyzed. As shown in Figures 1a and c , EBPd mRNA levels rapidly increase with peak levels 1 day after the induction of UUO. Next, we assessed C/EBPd protein levels by western blot again showing increased C/EBPd expression 1 day after UUO induction ( Figure 1b) . To identify the cell types expressing C/EBPd, kidney sections of control and obstructed wild-type mice were subjected to immunohistochemical analysis using a specific C/EBPd antibody. As shown in Figures 1c-f , in control kidney (Figure 1c ), some cells, probably monocytes, express C/EBPd. Upon UUO (Figures 1d-f 
C/EBPd Limits UUO-Induced Renal Fibrosis
One of the most important mediators in the genesis of renal interstitial fibrosis is TGF-b, 13, 36 whereas HGF levels counteract the action of TGF-b. 36 Consequently, we next determined whether C/EBPd modifies TGF-b and/or HGF production by analyzing both proteins in kidney homogenates of wild-type and C/EBPd-deficient mice subjected to the UUO model. As shown in Figure 2 , active TGF-b (Figure 2a ) and HGF (Figure 2b ) levels increased over time during UUO in wild-type animals. Interestingly, active TGF-b levels were two times higher in C/EBPd-deficient mice as compared with wild-type mice 7 days after induction of UUO, whereas HGF levels were significantly attenuated in C/ EBPd-deficient mice at day 7.
One of the major hallmarks of renal fibrosis is the accumulation of ECM proteins in the interstitium, 9,14,36 and consequently we analyzed collagen type I deposition in the obstructed kidneys by immunohistochemistry. As shown in Figures 2c-g, collagen type I was highly present in obstructed kidneys 7 days after induction of UUO. Interestingly, collagen type I levels were significantly higher in C/EBPd-deficient animals compared with wild-type mice (Figures 2c-g ). Together, these results suggest that C/EBPd limits renal fibrosis during obstructive nephropathy. 
C/EBPd Protects Against Tubular Injury
Tubular injury directly drives the formation of interstitial fibrosis. 37 Consequently, we assessed the contribution of C/ EBPd to the development of tubular injury. As shown in Figure 3 , UUO led to tubular injury in both wild-type and C/ EBPd-deficient animals. Interestingly, UUO-induced tubular damage was increased in C/EBPd-deficient mice 1 and 3 days post obstruction as compared with wild-type mice. This difference in tubular damage was not observed anymore at day 7 post obstruction, but at this time point end-stage renal disease was reached and tubular injury scores were close to maximum in both genotype groups. C/EBPd thus limits UUO-induced tubular injury.
The Role of C/EBPd in the Balance Between Proliferation and Apoptosis
To determine whether the increased tubular injury in C/EBPd-deficient obstructed kidneys was related to a distortion in the balance between proliferation and apoptosis, we assessed the number of proliferating and apoptotic cells immunohistochemically. As shown in Figures 4a-c , the number of Ki67-positive proliferating cells increased after the induction of UUO with peak levels at day 3. The number of proliferating cells was significantly increased in C/EBPddeficient mice as compared with wild-type mice at day 3 after the induction of UUO. However, the difference is rather small (11.5%). As shown in Figures 4d-f , the number of cleaved caspase-3-positive apoptotic cells also increased over time with peak levels at day 7 after the induction of UUO. The increased numbers of apoptotic cells did, however, not significantly differ between the two genotypes. Overall, C/EBPd seems to slightly affect proliferation without affecting apoptosis during UUO, and the minimal alteration in the proliferation/apoptosis balance does not seem to explain the protective effect of C/EBPd on fibrosis.
C/EBPd does not Affect the Inflammatory Response upon UUO
Next to proliferation/apoptosis, an early event in chronic obstructed nephropathy is a progressive inflammatory response as reflected by the recruitment of macrophages. 4 In order to assess whether differential macrophage influx correlated with the observed difference in fibrosis in wildtype and C/EBPd-deficient mice, we assessed F4/80-positive macrophages in the obstructed kidneys. As shown in Figures 5a-c, macrophage numbers increased drastically between 3 and 7 days after the induction of UUO. However, the number of macrophages did not differ between wild-type and C/EBPd-deficient obstructed kidneys, suggesting that macrophage infiltration does not contribute to the protective effect of C/EBPd on fibrosis.
C/EBPd Increases Vascular Leakage
Renal microvasculature injury constitutes an important mechanism in renal fibrosis, and disruption of the endothelial integrity may potentiate fibrosis after obstruction of the ureter. Consequently, we assessed the extent of edema in both wild type and C/EBPd deficient at day 3 and 7 after the 
DISCUSSION
Independent of the primary cause, tubulointerstitial fibrosis is the final common pathway of many chronic kidney diseases that finally leads to ESRD. It is thus important to get better insight into the mechanisms underlying renal fibrosis in order to design new therapeutic strategies for limiting progressive renal disease. Interestingly, C/EBPd recently emerged as a transcription factor involved in both proliferation and inflammation. Considering the importance of proliferation and inflammation in tubulointerstitial fibrosis, we hypothesized that C/EBPd would drive fibrosis and consequently that C/EBPd deficiency would limit renal fibrosis. Unexpectedly, however, we show that C/EBPd actually attenuates fibrotic responses in the well-established UUO model of renal fibrosis as evident from increased TGF-b levels and collagen type I synthesis in C/EBPd-deficient obstructed kidneys compared with wild-type obstructed kidneys.
To elucidate the underlying mechanism by which C/EBPd would limit UUO-induced fibrosis, we initially focused on the proliferation/apoptosis balance. A distortion in this balance is suggested to contribute to UUO-induced fibrosis, whereas C/EBPd is particularly well known to regulate the proliferation/apoptosis balance. In the current study, we did not observe major differences in either proliferation or apoptosis in obstructed wild-type vs C/EBPd-deficient kidneys. This result may be surprising in light of the role of C/EBPd in proliferation/apoptosis, although one should realize that most of the studies implying C/EBPd in proliferation/apoptosis have been performed in cancer cells. Indeed, C/EBPd induces growth arrest and apoptosis in different cancer cell lines, 16, 22 whereas C/EBPd silencing by promoter hypermethylation is positively correlated with tumor progression. 38, 39 Importantly, however, C/EBPd also drives pro-apoptotic gene expression during mammary gland involution, 19, 20 and C/EBPd is thus not only involved in proliferation/apoptosis in a cancer setting. Most likely, C/EBPd exerts its effect on proliferation/apoptosis in a cell type dependent manner, and C/EBPd may not be considered a general driver of apoptosis.
Accumulating evidence suggest that C/EBPd might have an important role in macrophage function, and we recently showed that migration of macrophages upon Klebsiellainduced pneumonia was significantly decreased in C/EBPddeficient mice. 24 In the current study, we did, however, not observe any difference in macrophage numbers in obstructed kidneys of wild-type and C/EBPd-deficient mice. Consequently, C/EBPd does not limit renal fibrosis during obstructive nephropathy by modifying macrophage recruitment. Alternatively, C/EBPd could modify macrophage function during UUO. However, macrophage-dependent TGF-b production, a key process in UUO-induced fibrosis, is not affected by C/EBPd in vitro. Indeed, TGF-b production is similar in wild-type and C/EBPd-deficient bone marrowderived macrophages and/or tubular epithelial cells (unpublished data). Overall, C/EBPd-driven processes in macrophages do not seem to explain the observed difference in UUO-induced fibrosis.
As already touched upon, another hallmark of the development of renal fibrosis is microvasculature injury, 40 and disruption of the endothelial integrity may potentiate fibrosis after obstruction of the ureter. 6, 7 Interestingly, C/EBPd limits UUO-induced vascular leakage as evident from a significant increase in edema in obstructed kidneys from C/EBPddeficient mice as compared with wild-type mice. It is tempting to speculate that C/EBPd-dependent prevention of vascular barrier disruption indeed limits subsequent interstitial fibrosis, but ongoing studies are needed to prove or refute this hypothesis.
It is well established that aSMA levels are increased during UUO. Indeed, we also observed increased levels of aSMA both on the mRNA and protein level, but the increase was similar in wild-type and C/EBPd-deficient obstructed kidneys (Supplementary Figure 1) . This is in contrast to recent data that aSMA is regulated by C/EBPd in Habu-venom-induced glomerulonephritis. 29 More importantly, the authors also state, but do not show, that aSMA mRNA levels are reduced in C/EBPd-deficient mice during UUO. At this moment, we do not have a proper explanation for these seemingly contradictory results, although it is difficult to compare our data with these unpublished observations, as no experimental details are available.
Overall, we show that C/EBPd limits UUO-induced renal fibrosis by a mechanism not related to the proliferation/ apoptosis balance or infiltration of macrophages. Irrespective of the actual mechanism, however, we pinpoint C/EBPd as a key factor in the prevention of renal interstitial fibrosis.
